FDA clears PET/CT scanner from Siemens Healthineers

The U.S. Food and Drug Administration has cleared a new PET/CT device from Siemens Healthineers, the company announced recently.

The Biograph Vision.X is a positron emission tomography/computed tomography scanner boasting one of the industry’s fastest times of flight (178 picoseconds). Tiny crystals allow for higher spatial resolution, with the Biograph able to deliver an estimated 20% performance improvement, bolstering throughput while reducing radiotracer costs.

“The Biograph Vision.X’s record-shattering, ultrafast time of flight delivers an image resolution that allows even the smallest lesions to rise above the noise,” James Williams, PhD, head of Siemens Healthineers’ molecular imaging division, said in a Nov. 22 company announcement. “This extremely high level of resolution can help physicians detect small lesions and provide patients with a precise diagnosis.”

Siemens also touted the scanner’s built-in artificial intelligence capabilities, allowing users to increase operational efficiency and accelerate patient workflows. The Biograph Vision.X additionally offers a large 78-centimeter bore, allowing for easier positioning of bariatric patients or radiotherapy devices.

Marty Stempniak

Marty Stempniak has covered healthcare since 2012, with his byline appearing in the American Hospital Association's member magazine, Modern Healthcare and McKnight's. Prior to that, he wrote about village government and local business for his hometown newspaper in Oak Park, Illinois. He won a Peter Lisagor and Gold EXCEL awards in 2017 for his coverage of the opioid epidemic. 

Around the web

The new F-18 flurpiridaz radiotracer is expected to help drive cardiac PET growth, but it requires waiting between rest and stress scans. Software from MultiFunctional Imaging can help care teams combat that problem.

News of an incident is a stark reminder that healthcare workers and patients aren’t the only ones who need to be aware around MRI suites.

The ACR hopes these changes, including the addition of diagnostic performance feedback, will help reduce the number of patients with incidental nodules lost to follow-up each year.